Skip to main
TVGN

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings is facing multiple factors that have led to a lowering of their price target and a change in rating from Buy to Hold. However, they recently announced a clinical milestone that expands their target coverage, increasing their potential patient access and enhancing the reach of their lead product candidate (TVGN 489) in both acute COVID-19 and Long COVID populations. Despite some risk factors, such as Clinical/Regulatory Risk, Partnership and Financial Risk, Commercial Risk, Legal and Intellectual Property Risk, and Market Share Risk, Tevogen Bio Holdings has a promising future with their expanding technology platform and potential in treating infectious diseases, cancers, and neurological disorders.

Bears say

Tevogen Bio Holdings is facing a significant risk of dilution as a result of its low stock price, hindering its ability to attract and retain investors and potentially impacting its financial stability and ability to advance its ExacTcell platform and develop its first clinical product TVGN 489. Additionally, the company is facing various risks in its operations, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks, which could impact its potential for success in the competitive healthcare industry. The company has also faced a decrease in its financial performance, lowering its price target from $5.0 to $2.0, reinforcing our negative outlook on the company's trajectory.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.